Artelo Biosciences (ARTL) Soars 40% After Securing Fully-Funded Glaucoma Trial Partnership

Key Highlights

• Artelo Biosciences (ARTL) climbed more than 40% during pre-market hours on March 18, 2026
• Gains followed news of a fully-funded clinical trial partnership with Belfast Health and Social Care Trust
• ART27.13, the company’s peripherally selective synthetic cannabinoid, will be evaluated in glaucoma and ocular hypertension patients
• Glaucoma UK and HSC R&D Division are providing complete funding, with initial patient enrollment anticipated in Q2 2026
• This development comes shortly after a 1-for-3 reverse stock split implemented on March 10, 2026

Shares of Artelo Biosciences (ARTL) skyrocketed over 40% in Wednesday’s pre-market session following the company’s disclosure of a fully-funded clinical research collaboration to evaluate its synthetic cannabinoid compound ART27.13 in glaucoma treatment.

Artelo Biosciences, Inc., ARTL

The investigator-led clinical trial was arranged through a partnership with Belfast Health and Social Care Trust (BHSCT). Complete financial backing comes from Glaucoma UK alongside the HSC R&D Division.

This pilot trial will use a randomized, cross-over design to evaluate ART27.13’s ability to reduce intraocular pressure (IOP) among individuals diagnosed with glaucoma or ocular hypertension.

ART27.13 functions as a peripherally selective synthetic cannabinoid receptor agonist. This mechanism enables it to activate cannabinoid receptors located in peripheral tissues—such as ocular structures—while avoiding central nervous system engagement.

Current glaucoma management relies heavily on topical eye drop formulations, which frequently face challenges related to patient compliance and sustained therapeutic efficacy. According to Artelo, ART27.13’s unique design may circumvent the psychotropic adverse effects that have historically hindered cannabinoid-based ophthalmic therapies.

Regulatory approval for the study protocol has already been obtained from an ethics review board and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Initial patient recruitment is projected to begin in Q2 2026.

Professor Augusto Azuara-Blanco will serve as principal investigator for the trial. He holds a position as clinical professor of ophthalmology at Queen’s University Belfast and brings extensive expertise in glaucoma research.

Glaucoma impacts over 80 million individuals globally and ranks among the primary causes of permanent vision loss. Elevated IOP represents the most significant modifiable risk factor for disease advancement.

Capital-Efficient Development Approach

CEO Greg Gorgas characterized the partnership as integral to the company’s resource-conscious development framework. Artelo’s strategy involves enabling external sponsors to finance this research while maintaining internal resources for ART27.13’s principal target indication—cancer-associated anorexia.

According to the agreement terms, Artelo’s responsibility is limited to supplying ART27.13 capsules as the Investigational Medicinal Product. All other financial obligations rest with the study’s external funding sources.

Company’s Financial Position

The dramatic pre-market rally occurs amid significant financial headwinds. Artelo disclosed a net loss of $12.9 million for fiscal year 2025 ending December 31, representing an increase from the $9.8 million loss recorded in the prior year.

The company’s cash position combined with investments totaled only $0.6 million at year-end. InvestingPro’s Financial Health Score assigns the company a “WEAK” rating.

A 1-for-3 reverse stock split was executed on March 10, 2026. This consolidation reduced outstanding common shares from approximately 2.1 million to 708,323 shares.

Before Wednesday’s surge, ARTL had experienced a 67% decline throughout the preceding six-month period. The stock was valued at $4.85 with a market capitalization near $3.47 million ahead of the pre-market jump.

The glaucoma trial marks Artelo’s inaugural venture into ophthalmology and represents the company’s first externally-funded clinical research partnership.

The post Artelo Biosciences (ARTL) Soars 40% After Securing Fully-Funded Glaucoma Trial Partnership appeared first on Blockonomi.